Multinational Data

Filling critical evidence generation gaps with global oncology real-world data

Flatiron is a globally recognized leader in cancer-specific real-world data across the US—and now in the UK, Germany, and Japan. With deep data models encompassing unmatched biomarker variables and clinical depth, we provide rapid, compliant access to regulatory-grade data that reflects the entire patient journey.

Download fact sheet

Best-in-class, real-world data—developed with local infrastructure by in-country teams

Infrastructure

Flatiron's tailored in-country systems and processes enable curation of raw source data from site EHRs, including unstructured records. Our multi-site model will support continued expansion in key markets.

Quality and standardization

Flatiron RWD is traceable to source with rigorous quality management maintained at every stage. Aligned to our US data models, standardized data processing enables cross-market comparison and analysis.

Accessibility

Patient-level data, custom datasets, and services are readily available via our Trusted Research Environment with embedded analytical workflows and user support. Broad data access agreements eliminate the need for individual site contracts.

Legal and compliance

Flatiron's in-country tech infrastructure is fully compliant with local regulatory requirements and secondary health data use norms.

Data sources from our oncology healthcare networks around the world

UK

Flatiron's model and approach have received approval from the NHS Health Research Authority, facilitating access across multiple major NHS Trusts in the UK. This endorsement has paved the way for ongoing research collaboration with NICE, focusing on the use of EHR-derived real-world data (RWD) to support health technology assessment (HTA) decision-making.

Learn more about Flatiron UK

Germany

Our representative network spans community oncology and urology practices as well as large hospitals. We are the only oncology real-world evidence (RWE) provider in Germany directly integrating with EHR systems, enabling curation of the full patient journey and consistency of data across sites. Our approach safeguards full compliance with federal, national, and EU data protection laws.

Learn more about Flatiron Germany

Japan

We maintain long-term strategic partnerships with multiple leading cancer centers and university hospitals, ensuring that development and utilization of our research-ready datasets are reviewed by the Institutional Review Boards (IRBs) of each partner site. Our operations strictly adhere to local privacy and security laws, such as the APPI, to ensure robust compliance and data protection.

Learn more about Flatiron Japan

Blythe Adamson, PhD, MPH

Head, Outcomes Research & Evidence Generation, International, on the growing demand for local real world data in Europe and Asia

"We can now conduct cross-country studies securely, using variables that have been purpose built for harmonization and pooling."

still frame from a video of Blythe Adamson speaking

Disease-specific data models

Our multinational datasets contain a combination of structured and unstructured data elements for the below cancer types with additional indications planned for 2025 based on customer demand. Ex-US and multi-country data is available via our Trusted Research Environment, ensuring full compliance with local regulatory requirements including GDPR and APPI.

Disease name	UK	Germany	Japan
Breast cancer
Non-small cell lung cancer
Prostate cancer
Colorectal cancer
Gastric cancer
Diffuse large B-cell lymphoma
Small-cell lung cancer
Bladder cancer
Multiple myeloma

By the numbers

90-day recency

EDMs are refreshed quarterly with 90-day recency

Teams of 100+

Flatiron has in-country teams of over 100 individuals, processing data into cancer-specific RWE datasets

10+ years

Flatiron leverages over 10 years of experience in delivering RWE adapted to the largest international oncology markets

Characterization of novel longitudinal oncology real world datasets in Germany and the UK: Biomarker prevalence findings

— Featured research

Given limited availability of oncology RWD in Europe, identifying new patient cohorts is critical for further pharmacoepidemiology studies. Read how Flatiron developed a fit-for-purpose dataset for potential use in comparative-effectiveness research across countries.

Read research summary

The consortium to advance HTA decision-making through RWE

Flatiron FORUM is our multi-stakeholder research collaboration that brings together Life Science Companies, HTA bodies and academics with the goal of enabling better HTA decision-making through the exemplar use of RWE and research methods.

Learn more about Flatiron FORUM